Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature

다국어 초록 (Multilingual Abstract)

Denosumab, which has been approved for the treatment of osteoporosis since 2010, is a fully humanised monoclonal antibody against a cytokine, receptor activator of nuclear factor kappa B ligand (RANKL), involved in bone resorption. Continued use of denosumab results in a potent and sustained decrease in bone turnover, an increase in bone mineral density (BMD), and a reduction in vertebral and hip fractures. The anti-resorptive effects of denosumab are reversible upon cessation, and this reversal is accompanied by a transient marked increase in bone turnover that is associated with bone loss, and of concern, an increased risk of multiple vertebral fractures. In this review, we outline the effects of denosumab withdrawal on bone turnover markers, BMD, histomorphometry, and fracture risk. We provide an update on recent clinical trials that sought to answer how clinicians can transition away from denosumab safely with follow-on therapy to mitigate bone loss and summarise the recommendations of various international guidelines.

참고문헌 (Reference)

1 Kondo H, "Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment" 38 : 894-902, 2020

2 Anastasilakis AD, "Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment : a prospective 2-year clinical trial" 34 : 2220-2228, 2019

3 Cummings SR, "Vertebral fractures after discontinuation of denosumab : a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension" 33 : 190-198, 2018

4 Solling AS, "Treatment with zoledronate subsequent to denosumab in osteoporosis : a randomized trial" 35 : 1858-1870, 2020

5 Lewiecki EM, "Treat-to-target for osteoporosis : is now the time" 98 : 946-953, 2013

6 Makras P, "The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis" 138 : 115478-, 2020

7 Zanchetta MB, "Significant bone loss after stopping long-term denosumab treatment : a post FREEDOM study" 29 : 41-47, 2018

8 Aubry-Rozier B, "Severe spontaneous vertebral fractures after denosumab discontinuation : three case reports" 27 : 1923-1925, 2016

9 Lamy O, "Severe rebound-associated vertebral fractures after denosumab discontinuation : 9 clinical cases report" 102 : 354-358, 2017

10 Eastell R, "Response to letter to the editor : "Pharmacological management of osteoporosis in postmenopausal women : an Endocrine Society Clinical Practice Guideline"" 104 : 3537-3538, 2019

11 Ferrari S, "Relationship between bone mineral density T-score and nonvertebral fracture risk over 10 years of denosumab treatment" 34 : 1033-1040, 2019

12 Popp AW, "Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics" 27 : 1917-1921, 2016

13 김부경 ; 김종화 ; 민용기, "Preventing Rebound-Associated Fractures after Discontinuation of Denosumab Therapy: A Position Statement from the Health Insurance Committee of the Korean Endocrine Society" 대한내분비학회 36 (36): 909-911, 2021

14 Lehmann T, "Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures" 28 : 3067-3068, 2017

15 Eastell R, "Pharmacological management of osteoporosis in postmenopausal women : an Endocrine Society Clinical Practice Guideline" 104 : 1595-1622, 2019

16 Meier C, "Osteoporosis drug treatment : duration and management after discontinuation : a position statement from the SVGO/ASCO" 147 : w14484-, 2017

17 Anastasilakis AD, "Multiple clinical vertebral fractures following denosumab discontinuation" 27 : 1929-1930, 2016

18 Trovas G, "Letter to the editor : Severe rebound-associated vertebral fractures after denosumab discontinuation : nine clinical cases report" 102 : 1086-, 2017

19 The American Society for Bone and Mineral Research, "Joint guidance on osteoporosis management in the era of COVID-19 from the ASBMR, AACE, Endocrine Society, ECTS & NOF" ASBMR

20 Anastasilakis AD, "Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment" 176 : 677-683, 2017

21 Cummings SR, "Goal-directed treatment for osteoporosis : a progress report from the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis" 32 : 3-10, 2017

22 Tsourdi E, "Fracture risk and management of discontinuation of denosumab therapy : a systematic review and position statement by ECTS" 106 : 264-281, 2021

23 Tripto-Shkolnik L, "Fracture incidence after denosumab discontinuation : real-world data from a large healthcare provider" 130 : 115150-, 2020

24 Freemantle N, "Final results of the DAPS(Denosumab Adherence Preference Satisfaction)study : a 24-month, randomized, crossover comparison with alendronate in postmenopausal women" 23 : 317-326, 2012

25 Ebina K, "Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis" 31 : 485-492, 2021

26 Bone HG, "Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass" 96 : 972-980, 2011

27 Reid IR, "Effects of denosumab on bone histomorphometry : the FREEDOM and STAND studies" 25 : 2256-2265, 2010

28 Miller PD, "Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy : a randomized blinded phase 2 clinical trial" 43 : 222-229, 2008

29 Brown JP, "Discontinuation of denosumab and associated fracture incidence : analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months(FREEDOM)trial" 28 : 746-752, 2013

30 Cummings SR, "Denosumab for prevention of fractures in postmenopausal women with osteoporosis" 361 : 756-765, 2009

31 Leder BZ, "Denosumab and teriparatide transitions in postmenopausal osteoporosis(the DATA-Switch study) : extension of a randomised controlled trial" 386 : 1147-1155, 2015

32 Black DM, "Continuing bisphosphonate treatment for osteoporosis : for whom and for how long" 366 : 2051-2053, 2012

33 Anastasilakis AD, "Comparative effect of zoledronate at 6 versus 18 months following denosumab discontinuation" 108 : 587-594, 2021

34 Anastasilakis AD, "Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation : systematic review and additional cases" 32 : 1291-1296, 2017

35 Brown JP, "Bone remodeling in postmenopausal women who discontinued denosumab treatment : off-treatment biopsy study" 26 : 2737-2744, 2011

36 Langdahl B, "Bone modeling and remodeling : potential as therapeutic targets for the treatment of osteoporosis" 8 : 225-235, 2016

37 Kendler DL, "Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab" 30 : 2437-2448, 2019

38 Popp AW, "Bone mineral density changes after 1 year of denosumab discontinuation in postmenopausal women with long-term denosumab treatment for osteoporosis" 103 : 50-54, 2018

39 Horne AM, "Bone loss after romosozumab/denosumab : effects of bisphosphonates" 103 : 55-61, 2018

40 Camacho PM, "American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis : 2020 update" 26 (26): 1-46, 2020

41 Everts-Graber J, "A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains" 35 : 1207-1215, 2020

42 Bone HG, "10 Years of denosumab treatment in postmenopausal women with osteoporosis : results from the phase 3 randomised FREEDOM trial and open-label extension" 5 : 513-523, 2017